Indian cancer biomarker market is expected to grow at a CAGR of around 12.0% during the forecast period. India is a strong market for cancer biomarkers particularly due to its large population base and large mortality due to cancer. Global cancer biomarker market has huge scope in India as biomarker development will enable in screening of large populations. It may depend on the specific use of a cancer biomarker. Earlier diagnosis of cancer through biomarkers will result in the reduction of financial stress over the population and government, minimizing the cost of adverse events. The fast and speedy diagnosis of cancer in country such as India with a population of 1.31 billion is required which can be achieved with biomarker development in the region. Further biomarker applications in diagnosis, monitoring of effects during treatment and surveillance of patients during or following treatment as well as treatment optimization will spur the growth of the market in this region.
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/indian-cancer-biomarker-market
There are many Indian companies in the Indian cancer biomarker that are striving to contribute significantly in the landscape. The companies are collaborating with many foreign companies for promoting biomarker and personalized medicine approach for treating cancer. Core Diagnostics, Nutech Cancer Biomarkers, Cancer Genetics, Biogenuix, BioServe Biotechnologies are contributing in the cancer biomarker market in India. In April 2017, Core Diagnostics partnered with a silicon-based life science company called CellMax Life. The objective was to introduce CellMax Life’s genetic cancer risk test and ctDNA-based liquid biopsy in Indian markets for faster diagnosis and cancer treatment. These diagnostic advancements are capable of reducing cancer mortality of India by offering personalized, precision cancer risk assessment and screening. Thus, such initiatives and activities by the companies led to the growth of the Indian cancer biomarker.
Browse for Full Report Description@ https://www.omrglobal.com/industry-reports/indian-cancer-biomarker-market
Market Segmentation
Indian Cancer Biomarker Market by Biomarker Type
- Genetic Biomarker
- Protein Biomarker
Indian Cancer Biomarkers Market by Cancer Type
- Lung Cancer
- Prostate Cancer
- Breast Cancer
- Colorectal Cancer
- Cervical Cancer
- Other
Indian Cancer Biomarkers Market by Applications
- Drug Discovery and Development
- Diagnosis
- Risk Assessment
- Prognostics
Indian Cancer Biomarker Market by Profiling Technology
- Omics Technology
- Immunoassays
- Cytogenetics
- Bioinformatics
Company Profiles
- Abbott laboratories Inc.
- Astellas Pharma Inc.
- Becton, Dickson and Co.
- Bio-Rad Laboratories, Inc.
- Danaher Corp.
- Hoffmann-La Roche Ltd.
- Merck and Co., Inc.
- Novartis AG
- Pfizer Inc.
- QIAGEN GmbH
- Thermo Fisher Scientific Inc.
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
